Verastem's 900 mg KRAS G12D dose posted a 50% confirmed response rate in second-line pancreatic cancer, and the company will take a chemotherapy-free regimen into a first-line Phase 3. The rival comparison is overall survival.
Newsletter
Pipeline, markets, policy, and science. Once a week.
Wound care is becoming one of big medtech's next frontiers, and Swedish wound-care leader Mölnlycke just announced a separation into an independent wound-care company. At the center of that landscape sits MediWound (NASDAQ: MDWD).
A Nature paper finds that one arginine transfer RNA, tRNA1 Arg(UCU), keeps prostate tumors on androgen receptor signaling. When it falls, cells slip into a lineage-plastic, AR-inhibitor-resistant state.
PhRMA sued CMS on October 7 over the GLOBE most-favored-nation rule for Medicare Part B. The final rule covers as few as four manufacturers and $440 million in projected savings. The suit's real target is the CMMI test authority beneath it.